Phase I clinical trial of fibronectin CH296-stimulated T cell therapy in patients with advanced cancer.

Phase I clinical trial of fibronectin CH296-stimulated T cell therapy in patients with advanced cancer.

BACKGROUND: Previous studies have demonstrated that less-differentiated T cells are ideal for adoptive T cell transfer therapy (ACT) and that fibronectin CH296 (FN-CH296) together with anti-CD3 resulted in cultured cells that contain higher amounts of less-differentiated T cells. In this phase I cli...

Full description

Bibliographic Details
Main Authors: Takeshi Ishikawa, Satoshi Kokura, Tatsuji Enoki, Naoyuki Sakamoto, Tetsuya Okayama, Mitsuko Ideno, Junichi Mineno, Kazuko Uno, Naohisa Yoshida, Kazuhiro Kamada, Kazuhiro Katada, Kazuhiko Uchiyama, Osamu Handa, Tomohisa Takagi, Hideyuki Konishi, Nobuaki Yagi, Yuji Naito, Yoshito Itoh, Toshikazu Yoshikawa
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2014-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3908868?pdf=render

Internet

http://europepmc.org/articles/PMC3908868?pdf=render

Similar Items